EGFR and neoplasm: CRIPTO desensitizes EGFR-mutant NSCLC tumor cells to EGFR-TKI treatment through CRIPTO-mediated Src activation, and inhibition of Src resensitizes CRIPTO-expressing cells to EGFR-TKI treatment.